- Home
- RLMD
as 01-22-2025 4:00pm EST
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | CORAL GABLES |
| Market Cap: | 11.5M | IPO Year: | N/A |
| Target Price: | $4.25 | AVG Volume (30 days): | 881.7K |
| Analyst Decision: | Hold | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.87 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.34 - $7.22 | Next Earning Date: | 03-18-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Relmada Therapeutics Inc. News
RLMD Breaking Stock News: Dive into RLMD Ticker-Specific Updates for Smart Investing
Simply Wall St.
21 days ago
US Penny Stocks To Watch In January 2025
Argus Research
a month ago
Daily – Vickers Top Insider Picks for 12/09/2024
GlobeNewswire
a month ago
Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017
Argus Research
2 months ago
Daily – Vickers Top Insider Picks for 12/06/2024
MT Newswires
2 months ago
Relmada Shares Continue Downward Spiral After Downgrades
TipRanks
2 months ago
Relmada reports DMC assessment indicates Phase 3 Reliance II trial is futile
Argus Research
2 months ago
Daily – Vickers Top Insider Picks for 12/05/2024
MT Newswires
2 months ago
Sector Update: Health Care Stocks Edge Lower Late Afternoon
Compare RLMD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RLMD Relmada Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.